James Hambro & Partners LLP Buys 27,697 Shares of Danaher Co. (NYSE:DHR)

James Hambro & Partners LLP grew its position in Danaher Co. (NYSE:DHR) by 9.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 309,594 shares of the conglomerate’s stock after acquiring an additional 27,697 shares during the period. Danaher accounts for approximately 2.8% of James Hambro & Partners LLP’s investment portfolio, making the stock its 21st biggest position. James Hambro & Partners LLP’s holdings in Danaher were worth $71,087,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Decker Retirement Planning Inc. bought a new stake in shares of Danaher during the fourth quarter worth about $31,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Danaher during the third quarter worth $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the third quarter worth $40,000. FSA Wealth Management LLC acquired a new stake in Danaher in the third quarter valued at $50,000. Finally, Darwin Wealth Management LLC bought a new position in Danaher during the 3rd quarter worth $55,000. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 0.1 %

Shares of Danaher stock opened at $245.95 on Monday. The company’s 50-day moving average price is $235.33 and its 200-day moving average price is $253.62. The company has a market cap of $177.65 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. Danaher Co. has a 12-month low of $225.42 and a 12-month high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on DHR shares. Robert W. Baird decreased their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Raymond James dropped their target price on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 21st. Stephens restated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. UBS Group reduced their target price on Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research note on Wednesday, October 23rd. Finally, Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target on the stock in a research note on Friday, December 13th. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.